An observational study in Erythropoietic Protoporphyria and Iron-deficiency, sponsored by Bispebjerg Hospital. Completed at 1 site in Denmark. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-02-23.
Sponsored by Bispebjerg Hospital · Observational
Giving oral iron to patients with erythropoietic protoporphyria (EPP) who is iron deficient is thought to be beneficial. This is, however, not well documented. The purpose of this study is to investigate the effect and safety of oral iron in patients with EPP who is taking iron tablets due to iron deficiency.
29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.
Browse Protoporphyria, Erythropoietic studies →Bispebjerg Hospital is the lead sponsor of 281 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with EPP taking oral iron tablets due to iron deficiency
Exclusion Criteria:
Change in erythrocyte protoporphyrin concentration
Time frame: Before treatment and after 6-8 weeks of treatment
Change in hemoglobin and iron parameters
Time frame: Before treatment and after 6-8 weeks of treatment
Adverse event
Time frame: 6-8 weeks of treatment
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Protoporphyria, Erythropoietic→
Bispebjerg Hospital